Core Viewpoint - The traditional Chinese medicine sector experienced a decline of 0.71% on January 14, with Wanbangde leading the drop, while the Shanghai Composite Index fell by 0.31% and the Shenzhen Component Index rose by 0.56% [1] Group 1: Market Performance - The closing price of Wanbangde was 16.76, down by 3.01%, with a trading volume of 266,800 shares and a transaction amount of 450 million [2] - The top gainers in the traditional Chinese medicine sector included Renhe Pharmaceutical, which closed at 6.32, up by 3.10%, with a trading volume of 925,100 shares and a transaction amount of 579 million [1] - The overall net outflow of main funds in the traditional Chinese medicine sector was 342 million, while retail investors saw a net inflow of 240 million [2] Group 2: Individual Stock Analysis - Renhe Pharmaceutical had a net inflow of 74.86 million from main funds, accounting for 12.92% of its total, while retail investors had a net outflow of 50.46 million [3] - Kunming Pharmaceutical saw a net inflow of 44.97 million from main funds, representing 17.50%, with a net outflow of 28.44 million from retail investors [3] - Yunnan Baiyao had a net inflow of 22.29 million from main funds, which is 3.32% of its total, while retail investors experienced a net outflow of 25.09 million [3]

上市公司：云铝股份（000807），云南铜业（000878），罗平锌电（002114），驰宏锌锗（600497）， 锡业股份（000960），云南锗业（002428），贵研铂业（600459），云煤能源（600792），云南白药 （000538），龙津药业（002750），昆药集团（600422），大理药业（603963），生物谷（833266）， 昆船智能（301311），华能水电（600025），南网储能（600995） 数据来源：国家统计局，智研咨询整理 相关报告：智研咨询发布的《2026-2032年中国工业云行业市场深度评估及投资机会预测报告》 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 2025年1-11月，云南省工业企业数（以下数据涉及的工业企业，均为规模以上工业企业，从2011年起， 规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为5802 个 ...

Core Viewpoint - The recent resignation of the chairman and vice chairman of Kunming Pharmaceutical Group has raised market speculation regarding the connection to the company's poor performance in 2025, with significant declines in revenue and net profit reported [1][2]. Group 1: Management Changes - The chairman, Wu Wendo, resigned on January 6, 2026, and was succeeded by Yu Xiang, while the vice chairman, Li Hongshen, submitted his resignation on January 8, 2026, both citing work adjustments [1]. - Wu Wendo's tenure as chairman was less than a year, having been appointed on January 22, 2025, with his term originally set to end on January 22, 2028 [3]. - Li Hongshen also had a similar tenure, with his term ending on the same date as Wu Wendo's [3]. Group 2: Financial Performance - In the first three quarters of 2025, Kunming Pharmaceutical Group reported a revenue of 4.751 billion yuan, a year-on-year decrease of 18%, and a net profit attributable to shareholders of 269 million yuan, down nearly 40% [1]. - The third quarter of 2025 saw a significant drop in performance, with revenue of 1.4 billion yuan, a 30% decline year-on-year, and a net profit of 71 million yuan, down 59% [1]. - The decline in performance was attributed to changes in drug distribution channels and price reductions from centralized drug procurement [1]. Group 3: New Leadership - Yu Xiang, the new chairman, has a background in management with a master's degree in business administration and has held various positions within the China Resources pharmaceutical sector [3]. - His previous roles include vice president of China Resources Sanjiu and general manager of several subsidiaries, indicating a strong alignment with the company's strategic direction [3]. Group 4: Market Reaction - Following the announcement of the management changes, Kunming Pharmaceutical Group's stock price experienced a slight increase, closing at 12.92 yuan per share, with a total market capitalization of 9.8 billion yuan [5].

Core Viewpoint - On January 7, Kunming Pharmaceutical Group announced that Li Hongshen has resigned from multiple positions including Vice Chairman and Director due to work adjustments, and he will no longer hold any position within the company [1][5]. Group 1: Executive Changes - Li Hongshen's resignation includes his roles as Vice Chairman, Director, and member of the Strategic and ESG Committee, as well as the Audit and Risk Control Committee [1][4]. - Recent executive changes at Kunming Pharmaceutical Group also include the resignation of Wu Wendo as Chairman, Yan Wei as President, and Li Lichun as Vice President, all citing work adjustments as the reason for their early departures [4][10]. Group 2: Financial Performance - For the third quarter of 2025, Kunming Pharmaceutical Group reported revenue of approximately 1.4 billion yuan, a year-on-year decrease of 30.19% [4][10]. - The net profit attributable to shareholders was 71 million yuan, reflecting a year-on-year decline of 59.03% [4][10]. - The company attributed the significant decline in revenue and net profit to ongoing model reconstruction and channel transformation, which have led to temporary sales pressure, compounded by delays in the nationwide collection of traditional Chinese medicine and integration of retail pharmacy terminals [4][10][11]. Group 3: Background of Li Hongshen - Li Hongshen, born in August 1978, holds a PhD in Economics and has a background in banking and tobacco industries, having served in various leadership roles prior to his tenure at Kunming Pharmaceutical Group [9]. - He has been in the position of Vice Chairman at Kunming Pharmaceutical Group since March 2024, and during this period, he did not receive compensation from the company but from related parties instead [4][9].

近日，昆药集团（600422）发布公告称，董事会于近日收到副董事长李泓燊递交的书面辞职报告。因工 作调整原因，李泓燊申请辞去公司十一届董事会副董事长、董事、董事会战略与ESG委员会委员、审计 与风险控制委员会委员职务。辞任后，李泓燊不再担任公司任何职务。 ...

■ 二、离任对公司的影响 根据相关法律、法规和《公司章程》的规定，李泓燊先生的辞职报告自送达公司董事会时生效，其离任 不会导致公司董事会成员低于法定最低人数，不会影响公司董事会正常运作。公司董事会将按照法定程 序尽快完成董事的补选工作。截至本公告日，李泓燊先生未持有公司股票，不存在应当履行而未履行的 承诺事项，李泓燊先生将按照相关规定做好交接工作。 李泓燊先生在担任公司副董事长期间，恪尽职守、勤勉尽责，为公司的长期可持续发展作出了重要贡 献。公司董事会谨对李泓燊先生在任职期间对公司发展作出的重要贡献表示衷心感谢！ 证券代码：600422 证券简称：昆药集团 公告编号：2026-004号 昆药集团股份有限公司关于董事离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 昆药集团股份有限公司（以下简称"公司"）董事会于近日收到副董事长李泓燊先生递交的书面辞职报 告。因工作调整原因，李泓燊先生申请辞去公司十一届董事会副董事长、董事、董事会战略与ESG委员 会委员、审计与风险控制委员会委员职务。辞任后，李泓燊先生 ...

北京商报讯（记者 王寅浩 宋雨盈）1月7日，昆药集团发布公告称，因工作调整原因，公司副董事长李 泓燊申请辞去公司十一届董事会副董事长、董事、董事会战略与ESG委员会委员、审计与风险控制委员 会委员职务。辞任后，李泓燊不再担任公司任何职务。 ...

证券代码：600422 证券简称：昆药集团 公告编号：2026-004号 特此公告。 昆药集团股份有限公司董事会 一、董事离任情况 | | | | 离任时 | 原定任 | 离任 | 是否继续在 上市公司及 | 具体职 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 离任职务 | | | 期到期 | | | 务（如 | | | | | | 间 | 日 | 原因 | 其控股子公 | 适用） | 毕的公开 | | | | | | | | 司任职 | | 承诺 | | 李泓燊 | 副董事长、董事、董事会战 略与 ESG | 委员会委员、审计 | 2026.1.6 | 2028.1.22 | 工作 调整 | 否 | 无 | 否 | | | 与风险控制委员会委员 | | | | | | | | 二、离任对公司的影响 根据相关法律、法规和《公司章程》的规定，李泓燊先生的辞职报告自送达 公司董事会时生效，其离任不会导致公司董事会成员低于法定最低人数，不会影 响公司董事会正常运作。公司董事会将按照法定程序尽快完成董事的补选 ...

每经头条（nbdtoutiao）——十年首现，沪指连续站稳关键位置！高盛：建议高配中国股票！券商分析 师：人民币升值等因素加速跨境资本回流 每经AI快讯，昆药集团1月7日晚间发布公告称，因工作调整原因，李泓燊先生申请辞去公司十一届董 事会副董事长、董事、董事会战略与ESG委员会委员、审计与风险控制委员会委员职务。辞任后，李泓 燊先生不再担任公司任何职务。 （记者 曾健辉） ...

Group 1 - The core point of the article is the significant management shake-up at Kunming Pharmaceutical Group, with the resignation of key executives and the appointment of new leadership from China Resources Sanjiu, indicating a deeper integration and control by the parent company amid performance pressures [1][2][3] Group 2 - The resignations include Chairman Wu Wendo, President Yan Wei, and Vice President Li Lichun, with Yu Xiang and Zhong Jiang taking over as Chairman and President, respectively, marking a shift in management less than a year after the last major changes [2][3] - The new management team has strong ties to China Resources, with Yu Xiang having extensive experience in the OTC and health sectors, and Zhong Jiang having risen through the ranks within the company [2][3] Group 3 - Kunming Pharmaceutical's performance has deteriorated significantly, with revenue dropping by 18.08% to 4.751 billion yuan and net profit declining by 39.42% to 269 million yuan in the first three quarters of 2025, marking the lowest figures in six years [4][5] - The company attributes its struggles to transitional pains from channel reforms and external pressures, including delayed execution of national traditional Chinese medicine procurement [5] Group 4 - The management changes are part of a broader strategy by China Resources to shift focus from external acquisitions to internal integration and operational efficiency, as evidenced by the expansion of the board from 9 to 15 members, with new directors from core management [3][6] - Recent personnel changes across various subsidiaries of China Resources indicate a strategic pivot towards internal consolidation following years of aggressive expansion [6][7] Group 5 - The success of the new management will depend on their ability to leverage their experience in the OTC sector to reverse the current downward trend in performance and align Kunming Pharmaceutical with the broader strategic goals of China Resources [5][7]